$KOPN

KOPIN CORP (KOPN): Results of Operations and Financial Condition

KOPIN CORP (KOPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Kopin Corporation Reports Second Quarter 2026 Financial Results Three Major Milestones Achieved in U.S. Army Color MicroLED Program, Including Record-Setting 150,000+ Nit Full-Color Brightness and Installation of U.S. Bonding Capability,

Original reporting
Published Aug 10, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$KOPN
Bullish
medium confidence
Mentioned
$KOPN
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$KOPNBullishMed
01

Why it matters

Traders can use the disclosed Q2 revenue mix and management’s reiterated outlook for 2H 2026 and progress toward 4Q GAAP profitability, while monitoring whether late-August DDP Phase 2 awards convert prototype orders into production volume.

02

Market read

The filing is a combined earnings and execution update, with specific defense program milestones and order momentum that can re-rate expectations for 2H 2026 and 2027.

03

What to watch

Cost of product revenues remains high as a share of net product revenues (86% vs 94% prior year), and the filing is preliminary unaudited, so margins and conversion to production orders remain key uncertainties.

Relevance 7/10Novelty 7/10Timing: filed pre-market/after close on Aug 10, 2026 with Q2 preliminary results and forward-looking expectations

Background

This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 providing preliminary unaudited Q2 2026 financial results and operational updates across Kopin’s MicroLED, Sentinel FPV, and Neural I/o initiatives.

Company-level read

Ticker impact

$KOPNBullishMedium confidence
Context

Kopin reported Q2 2026 results and said it achieved color MicroLED milestones plus received multiple Sentinel FPV prototype orders tied to U.S. drone programs.

Expected impact

Bias to upside on any market reaction, with follow-through risk if prototype-to-production conversion timing slips.

Evidence & confidence

Revenues rose 51% YoY and non-product revenue jumped 433%, while management reiterated expectations for a solid 2H and progress toward GAAP profitability, supported by specific program milestones and order momentum.

Market effects

Supports the narrative of accelerating U.S. defense microdisplay and AI interconnect demand, potentially improving sentiment for niche optical and microdisplay suppliers.

Limited direct regional read-through beyond Westborough and Dallas engineering footprint expansion.

Primarily U.S.-program driven, with mention of international demand for color MicroLED in HUDs and sights.

Counterpoint

Prototype orders and program milestones may not translate into near-term revenue, and the large non-product revenue jump could be grant/collaboration timing rather than durable product demand.

Key entities

  • Kopin Corporation

    Nasdaq-listed optical systems and microdisplay supplier reporting Q2 2026 preliminary results and defense/AI program milestones.

  • U.S. Army IBAS initiative

    Industrial Base Analysis and Sustainment initiative referenced for Kopin’s color MicroLED development milestones.

  • U.S. Government Drone Dominance Program (DDP)

    Program under which Kopin says it received multiple Sentinel FPV prototype orders, with volume orders expected after Phase 2 awards.

  • Fabric.AI

    Referenced as a collaboration partner for Kopin’s Neural I/o AI infrastructure initiative.

Related articles

$KOPNHighAI 9/10

Why is Kopin stock surging today?

Kopin Corp (KOPN) shares rose about 26% after the company reported Q2 2026 results above expectations, with revenue of $12.7M versus $11.75M consensus and net income of $0.9M versus a $5.2M loss a year earlier. Kopin also guided to full GAAP profitability by Q4 2026 and said its Neural I/o MicroLED optical interconnect with Fabric.AI remains on track for a CES 2027 demo.

$KOPNMedAI 9/10

Kopin (NASDAQ:KOPN) Stock Price Down 8.4% – Time to Sell?

Kopin (NASDAQ:KOPN) shares fell 8.4% on Friday to about $5.54, after trading as low as $5.56; volume was 1.79M shares versus a 5.51M average. The company reported Q1 EPS of -$0.02 (vs -$0.01 consensus) on revenue of $10.55M (vs $9.96M). Analysts cited mixed ratings, with a consensus target of $7.15.

$SHLSHighAI 9/10

Shoals Technologies (SHLS) Q2 2026 Earnings Call Transcript

Shoals Technologies Group (SHLS) reported Q2 2026 revenue of $163.4 million, up 47.4% year over year, and adjusted EBITDA of $31.6 million. Backlog and awarded orders rose to $801.4 million. Management reaffirmed Q3 revenue guidance of $150 million to $170 million and full-year 2026 revenue of $600 million to $640 million, citing solar demand and growth in BESS.

$BRBRMedAI 8/10

BellRing Brands (BRBR) Q3 2026 Earnings Call Transcript

BellRing Brands (BRBR) reported Q3 FY2026 net sales of $570.4 million, up 4.2%, with adjusted EBITDA of $78.3 million, down from $120.3 million, citing input cost inflation and higher freight. Adjusted gross margin fell to 27.7%. FY2026 outlook: net sales $2.335B-$2.375B and adjusted EBITDA $275M-$295M. Share repurchases totaled $133.1M.

$XTNTMed

Xtant Medical Holdings, Inc. Q2 2026 Earnings Call Summary

Xtant Medical Holdings reported Q2 2026 revenue headwinds tied to divestitures to Companion Spine and the end of certain license revenue. Biologics softness and amniotic membrane weakness persisted, while 17 new Dilon reps weighed on sales. Full-year 2026 guidance was cut to $99M-$103M; cash fell to $9.9M. Gross margin was 57.9%.

Med

BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary

BioHarvest Sciences reported a Q2 2026 earnings call focused on shifting capital from D2C to CDMO. It secured a CDMO manufacturing and supply deal for a rare fragrance, targeting $20m to $30m revenue in 2027-2028 and $180m over five years, with limited production in H1 2027. 2026 revenue guidance was cut to $37m-$40m, and it expects CDMO EBITDA loss of $1.5m-$2.5m and consolidated EBITDA breakeven in 2027.